Kanamycin A in the context of "Flavr Savr"

Play Trivia Questions online!

or

Skip to study material about Kanamycin A in the context of "Flavr Savr"

Ad spacer

⭐ Core Definition: Kanamycin A

Kanamycin A, often referred to simply as kanamycin, is an antibiotic used to treat severe bacterial infections and tuberculosis. It is not a first line treatment. It is used by mouth, injection into a vein, or injection into a muscle. Kanamycin is recommended for short-term use only, usually from 7 to 10 days. Since antibiotics only show activity against bacteria, it is ineffective in viral infections.

Common side effects include hearing and balance problems. Kidney problems may also occur. Kanamycin is not recommended during pregnancy as it may harm the baby. It is likely safe during breastfeeding. Kanamycin is in the aminoglycoside family of medications. It has the weakest antibacterial capabilities of all compounds in this family when used clinically, which is partially due to its increased toxicity in comparison to other aminoglycosides. It works by blocking the production of proteins that are required for bacterial survival.

↓ Menu

>>>PUT SHARE BUTTONS HERE<<<

👉 Kanamycin A in the context of Flavr Savr

Flavr Savr (also known as CGN-89564-2; pronounced "flavor saver"), a genetically modified tomato, was the first commercially grown genetically engineered food to be granted a license for human consumption. It was developed by the Californian company Calgene in the 1980s. The tomato has an improved shelf-life, increased fungal resistance, and a slightly increased viscosity compared to its unmodified counterpart. It was meant to be harvested ripe for increased flavor for long-distance shipping. The Flavr Savr contains two genes added by Calgene; a reversed antisense polygalacturonase gene, which inhibits the production of a rotting enzyme, and a gene responsible for the creation of APH(3')II, which confers resistance to certain aminoglycoside antibiotics, including kanamycin and neomycin.

On May 18, 1994, the FDA completed its evaluation of the Flavr Savr tomato and the use of APH(3')II, concluding that the tomato "is as safe as tomatoes bred by conventional means" and "that the use of aminoglycoside 3'-phosphotransferase II is safe for use as a processing aid in the development of new varieties of tomato, rapeseed oil, and cotton intended for food use." It was first sold in 1994, and was only available before production ceased in 1997. Calgene made history, but mounting costs prevented the company from becoming profitable, and it was eventually acquired by Monsanto Company.

↓ Explore More Topics
In this Dossier